187 related articles for article (PubMed ID: 38040834)
61. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
[TBL] [Abstract][Full Text] [Related]
62. Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors.
Wu Q; Xia Y; Xiong X; Duan X; Pang X; Zhang F; Tang S; Su J; Wen S; Mei L; Cannon RD; Ji P; Ou Z
Front Pharmacol; 2023; 14():1169608. PubMed ID: 37180717
[TBL] [Abstract][Full Text] [Related]
63. It takes two to tango: the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy.
Sheban F
Front Immunol; 2023; 14():1183578. PubMed ID: 37359522
[TBL] [Abstract][Full Text] [Related]
64. Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Revach OY; Cicerchia AM; Shorer O; Petrova B; Anderson S; Park J; Chen L; Mehta A; Wright SJ; McNamee N; Tal-Mason A; Cattaneo G; Tiwari P; Xie H; Sweere JM; Cheng LC; Sigal N; Enrico E; Miljkovic M; Evans SA; Nguyen N; Whidden ME; Srinivasan R; Spitzer MH; Sun Y; Sharova T; Lawless AR; Michaud WA; Rasmussen MQ; Fang J; Palin CA; Chen F; Wang X; Ferrone CR; Lawrence DP; Sullivan RJ; Liu D; Sachdeva UM; Sen DR; Flaherty KT; Manguso RT; Bod L; Kellis M; Boland GM; Yizhak K; Yang J; Kanarek N; Sade-Feldman M; Hacohen N; Jenkins RW
bioRxiv; 2024 Mar; ():. PubMed ID: 38405985
[TBL] [Abstract][Full Text] [Related]
65. Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion.
Li F; Wang Y; Chen D; Du Y
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338674
[TBL] [Abstract][Full Text] [Related]
66. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
67. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13
Liu B; Zhang Y; Wang D; Hu X; Zhang Z
Nat Cancer; 2022 Sep; 3(9):1123-1136. PubMed ID: 36138134
[TBL] [Abstract][Full Text] [Related]
68. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
69. Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune "cold" tumors.
Xiao G; Zhao Y; Wang X; Zeng C; Luo F; Jing J
Front Immunol; 2023; 14():1279221. PubMed ID: 37942337
[TBL] [Abstract][Full Text] [Related]
70. Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade.
Tian W; Qin G; Jia M; Li W; Cai W; Wang H; Zhao Y; Bao X; Wei W; Zhang Y; Shao Q
Front Immunol; 2023; 14():1198551. PubMed ID: 37398674
[TBL] [Abstract][Full Text] [Related]
71. Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy.
Cao Y; Ding S; Zeng L; Miao J; Wang K; Chen G; Li C; Zhou J; Bian XW; Tian G
ACS Appl Mater Interfaces; 2021 Nov; 13(45):53504-53518. PubMed ID: 34704726
[TBL] [Abstract][Full Text] [Related]
72. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Zhou X; Ni Y; Liang X; Lin Y; An B; He X; Zhao X
Front Immunol; 2022; 13():915094. PubMed ID: 36189283
[TBL] [Abstract][Full Text] [Related]
73. TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer.
Li Y; Jiang X; Luo T; Xia J; Lee MJ; Weichselbaum RR; Lin W
Biomaterials; 2022 Nov; 290():121831. PubMed ID: 36240687
[TBL] [Abstract][Full Text] [Related]
74. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
75. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy.
Sun M; Li Y; Zhang W; Gu X; Wen R; Zhang K; Mao J; Huang C; Zhang X; Nie M; Zhang Z; Qi C; Cai K; Liu G
Acta Biomater; 2023 Aug; 166():552-566. PubMed ID: 37236575
[TBL] [Abstract][Full Text] [Related]
76. Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade.
Fang T; Cao X; Wang L; Chen M; Deng Y; Chen G
Bioact Mater; 2024 Feb; 32():530-542. PubMed ID: 38026439
[TBL] [Abstract][Full Text] [Related]
77. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
78. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939
[TBL] [Abstract][Full Text] [Related]
79. Multifunctional nanoparticles precisely reprogram the tumor microenvironment and potentiate antitumor immunotherapy after near-infrared-II light-mediated photothermal therapy.
Ge Y; Zhang J; Jin K; Ye Z; Wang W; Zhou Z; Ye J
Acta Biomater; 2023 Sep; 167():551-563. PubMed ID: 37302731
[TBL] [Abstract][Full Text] [Related]
80. Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects.
Modur V; Muhammad B; Yang JQ; Zheng Y; Komurov K; Guo F
Cell Rep; 2023 Apr; 42(4):112364. PubMed ID: 37043352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
